1. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
- Author
-
Conforti, F, Zucali, P, Pala, L, Catania, C, Bagnardi, V, Sala, I, Della Vigna, P, Perrino, M, Zagami, P, Corti, C, Stucchi, S, Barberis, M, Guerini-Rocco, E, Di Venosa, B, De Vincenzo, F, Cordua, N, Santoro, A, Giaccone, G, Martino De Pas, T, Conforti F., Zucali P. A., Pala L., Catania C., Bagnardi V., Sala I., Della Vigna P., Perrino M., Zagami P., Corti C., Stucchi S., Barberis M., Guerini-Rocco E., Di Venosa B., De Vincenzo F., Cordua N., Santoro A., Giaccone G., Martino De Pas T., Conforti, F, Zucali, P, Pala, L, Catania, C, Bagnardi, V, Sala, I, Della Vigna, P, Perrino, M, Zagami, P, Corti, C, Stucchi, S, Barberis, M, Guerini-Rocco, E, Di Venosa, B, De Vincenzo, F, Cordua, N, Santoro, A, Giaccone, G, Martino De Pas, T, Conforti F., Zucali P. A., Pala L., Catania C., Bagnardi V., Sala I., Della Vigna P., Perrino M., Zagami P., Corti C., Stucchi S., Barberis M., Guerini-Rocco E., Di Venosa B., De Vincenzo F., Cordua N., Santoro A., Giaccone G., and Martino De Pas T.
- Abstract
Background: Patients with advanced type B3 thymoma and thymic carcinoma resistant to chemotherapy have few treatment options. We report the efficacy and safety results of the combination of the anti-PD-L1 inhibitor avelumab with the anti-angiogenesis drug axitinib in patients with advanced type B3 thymoma and thymic carcinoma. Methods: CAVEATT was a single-arm, multicentre, phase 2 trial, conducted in two Italian centres (the European Instituteof Oncology and the Humanitas Institute, Milan) in patients with histologically confirmed type B3 thymoma or thymic carcinoma, with advanced stage of disease who had progressed after at least one line of platinum-based chemotherapy. Previous treatment with an anti-angiogenesis drug was allowed but not with immune checkpoint inhibitors. Other inclusion criteria were age 18 years or older, an Eastern Cooperative Oncology Group performance status of 0–2, progressive disease, and presence of measurable disease according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Patients received avelumab 10 mg/kg intravenously every 2 weeks and axitinib 5 mg orally twice daily until disease progression or unacceptable toxicity. The primary endpoint was the centrally assessed overall response rate according to RECIST version 1.1. Patients who received at least one cycle of treatment and had at least one CT scan after treatment start at scheduled time point by protocol were judged assessable for response and were included in efficacy and safety analyses. This study is registered with EUDRACT, 2017–004048–38; enrolment is completed and follow-up is ongoing. Findings: Between April 22, 2019, and June 30, 2021, 32 patients were enrolled. 27 patients had a thymic carcinoma, three a type B3 thymoma, and two a mixed type B3 thymoma and thymic carcinoma. 29 (91%) of 32 patients had stage IVB disease and 13 (41%) of 32 had been pretreated with an anti-angiogenesis drug. 11 of 32 patients had an overall response; thus the overall
- Published
- 2022